DXCM 50.93 Dexcom Inc $DXCM Hit a 52 week high of 52.08 Currently at 50.93 +6.30 +14.12% With a day low of 46.61 and a total volume of 2,408,500.
DXCM Dexcom Inc Recent Headline News
Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 32.13 (+0.47), DXCM: 50.93 (+6.30), ANGO: 16.95 (+0.10), HOLX: 26.21 (-0.37)
Watch Out: Barbarians At The Gate For DexCom (DXCM)
at The Street - Fri Nov 07, 8:55AM CST
Trade-Ideas LLC identified DexCom (DXCM) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
DXCM: 50.93 (+6.30)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 32.13 (+0.47), DXCM: 50.93 (+6.30), FMI: 24.75 (-0.03), ANGO: 16.95 (+0.10)
DexCom, Inc. Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 3:02PM CST
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended September 30, 2014.
DXCM: 50.93 (+6.30)
FDA Approves Dexcom Software with Artificial Pancreas Algorithm
Business Wire - Thu Nov 06, 7:30AM CST
Dexcom, Inc., (NASDAQ
XCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4(R) PLATINUM CGM. The new Software 505 features the same advanced algorithm as used in artificial pancreas research around the world. The software will impact the performance of the Dexcom G4 PLATINUM, already considered the most accurate CGM system on the market today. The software will be made available free of charge to adult patients using the Dexcom G4 PLATINUM.
DXCM: 50.93 (+6.30)
DexCom Announces Upcoming Conference Presentations
Business Wire - Thu Oct 30, 7:30AM CDT
DexCom, Inc. (NASDAQXCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:
DXCM: 50.93 (+6.30)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 50.93 (+6.30), NVAX: 4.95 (-0.20), AGIO: 72.06 (-11.03), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), CELG: 106.45 (-0.69)
DexCom Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Oct 23, 7:31AM CDT
DexCom, Inc. (NASDAQXCM) today announced that it plans to release its third quarter 2014 financial results after market close on Thursday, November 6, 2014. Management will hold a conference call to review the company's third quarter 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference.
DXCM: 50.93 (+6.30)
FDA Approves Dexcom SHARE(TM), the First Remote Mobile Communications Device Used for Continuous Glucose Monitoring (CGM)
Business Wire - Mon Oct 20, 8:24AM CDT
Dexcom, Inc. (NASDAQXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its CGM remote mobile communications device: Dexcom SHARE. Dexcom SHARE, an accessory to the Dexcom G4(R) PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or "followers." These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere via their Apple(R) iPhone(R) or iPod(R) touch. With Dexcom SHARE, parents and personal caregivers can monitor a child's or loved one's glucose data from a remote location, giving them peace of mind and reassurance when they are apart.
DXCM: 50.93 (+6.30)
MFG, PGTI, MWIV, BKD, AREX, DXCM Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Oct 06, 6:29AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mizuho Financial Group Inc (NYSE:MFG), PGT Inc (NASDAQ
GTI), MWI Veterinary Supply Inc (NASDAQ:MWIV), BROOKDALE SENIOR LIVING INC. (NYSE:BKD), Approach Resources Inc (NASDAQ:AREX), DexCom Inc (NASDAQXCM) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
MFG: 3.56 (+0.02), DXCM: 50.93 (+6.30), MWIV: 154.24 (+1.73), PGTI: 9.62 (+0.03), BKD: 32.46 (-0.49), AREX: 10.73 (+1.88)
The Stunning Mobile Game Changer for Diabetics That Investors Can't Ignore
Leo Sun, The Motley Fool - Motley Fool - Sun Oct 05, 8:31AM CDT
Ever since Apple launched the first iPhone nearly seven years ago, developers have released mobile apps and connected devices to improve the lives of diabetes patients. These products helped diabetics track meals, insulin dosages, glucose...
JNJ: 108.20 (-0.81), DXCM: 50.93 (+6.30), MDT: 68.10 (-0.64), SNY: 45.69 (-0.17), AAPL: 109.01 (+0.31)
Technical Report on Health Care Equipment Stocks - Baxter Intl., Covidien, Becton Dickinson, Thoratec, and DexCom
PR Newswire - Wed Sep 17, 8:05AM CDT
On Tuesday, September 16, 2014, the NASDAQ Composite ended at 4,552.76, up 0.75%, the Dow Jones Industrial Average advanced 0.59%, to finish the day at 17,131.97, and the S&P 500 closed at 1,998.98, up 0.75%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index also advancing 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Baxter International Inc. (NYSE: BAX), Covidien PLC (NYSE: COV), Becton Dickinson and Company (NYSE: BDX), Thoratec Corporation (NASDAQ: THOR), and DexCom Inc. (NASDAQ: DXCM). Free research on these five companies can be accessed at:
BDX: 125.54 (-2.39), DXCM: 50.93 (+6.30), BAX: 70.61 (-0.99), COV: 92.08 (-0.52), THOR: 26.93 (+0.83)
3 Reasons Medtronic Inc. Stock Could Rise
Leo Sun, The Motley Fool - Motley Fool - Mon Sep 08, 12:01PM CDT
Last month, Medtronic 's first-quarter earnings topped consensus estimates on the top and bottom lines, as revenue rose 5% year over year to $4.27 billion and non-GAAP diluted earnings climbed 6% to $0.93 per share. Medtronic posted positive...
JNJ: 108.20 (-0.81), DXCM: 50.93 (+6.30), MDT: 68.10 (-0.64), COV: 92.08 (-0.52), STJ: 64.76 (-1.28)
Insider Trading Alert - NATI, DXCM And CNC Traded By Insiders
at The Street - Wed Sep 03, 10:15AM CDT
Stocks with insider trader activity include NATI, DXCM and CNC
CNC: 91.72 (-1.84), DXCM: 50.93 (+6.30), NATI: 32.58 (+0.06)
DexCom Up 14.2% Since SmarTrend Uptrend Call (DXCM)
Comtex SmarTrend(R) - Wed Aug 27, 9:26AM CDT
SmarTrend identified an Uptrend for DexCom (NASDAQXCM) on July 30th, 2014 at $40.28. In approximately 4 weeks, DexCom has returned 14.21% as of today's recent price of $46.00.
DXCM: 50.93 (+6.30)
DexCom Earnings Hindsight: Up 15.4% in Last 19 Days (DXCM)
Comtex SmarTrend(R) - Mon Aug 25, 7:24AM CDT
19 days ago, on August 6th, 2014, DexCom (NASDAQXCM) reported its earnings. Analysts, on average, expected a loss of $0.10 per share on sales of $52.3 million. DexCom actually reported a loss of $0.09 per share on sales of $58.8 million, beating EPS estimates by $0.01 and beating revenue estimates by $6.5 million. Shares of DexCom have climbed from $38.21 to $44.08, representing a gain of 15.4% since the company reported earnings 19 days ago.
DXCM: 50.93 (+6.30)
DexCom Has Returned 10.4% Since SmarTrend Recommendation (DXCM)
Comtex SmarTrend(R) - Tue Aug 19, 9:26AM CDT
SmarTrend identified an Uptrend for DexCom (NASDAQXCM) on July 30th, 2014 at $40.28. In approximately 3 weeks, DexCom has returned 10.39% as of today's recent price of $44.46.
DXCM: 50.93 (+6.30)
DexCom Earnings In Retrospect: Up 14.2% in the Last 12 Days (DXCM)
Comtex SmarTrend(R) - Mon Aug 18, 9:28AM CDT
When DexCom (NASDAQXCM) reported earnings 12 days ago on August 6th, 2014, analysts, on average, expected the company to report a loss of $0.10 on sales of $52.3 million. The company actually reported a loss of $0.09 per share on sales of $58.8 million, beating EPS estimates by $0.01 and beating revenue estimates by $6.5 million. Since the company's report, shares of DexCom have risen from $38.21 to $43.62, representing a gain of 14.2% in the past 12 days.
DXCM: 50.93 (+6.30)
DexCom Continues to Gain; Enters Data Integration Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:00PM CDT
Asante Snap Insulin Pump is the second insulin delivery device to be integrated into the DexCom, Inc. (DXCM) mobile app, the first being Insulet Corporation's OmniPod System.
ATEC: 1.39 (-0.06), PODD: 43.05 (+0.31), RTIX: 5.09 (+0.02), DXCM: 50.93 (+6.30)
Technical Coverage on Health Care Equipment Equities -- Boston Scientific, Covidien, Thoratec, Baxter Intl., and DexCom
PR Newswire - Wed Aug 13, 8:10AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average declined 0.06%, to finish the day at 16,560.54, and the S&P 500 closed at 1,933.75, down 0.16%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 699.06, down 0.14%, while the index has advanced 3.52% in the previous three months. Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Covidien PLC (NYSE:COV), Thoratec Corporation (NASDAQ: THOR), Baxter International Inc. (NYSE: BAX), and DexCom Inc. (NASDAQ: DXCM). Free research on these five companies can be accessed at:
BSX: 13.24 (-0.12), DXCM: 50.93 (+6.30), BAX: 70.61 (-0.99), COV: 92.08 (-0.52), THOR: 26.93 (+0.83)
DXCM Dexcom Inc Recent Headline News
Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 32.13 (+0.47), DXCM: 50.93 (+6.30), ANGO: 16.95 (+0.10), HOLX: 26.21 (-0.37)
Watch Out: Barbarians At The Gate For DexCom (DXCM)
at The Street - Fri Nov 07, 8:55AM CST
Trade-Ideas LLC identified DexCom (DXCM) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
DXCM: 50.93 (+6.30)
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 32.13 (+0.47), DXCM: 50.93 (+6.30), FMI: 24.75 (-0.03), ANGO: 16.95 (+0.10)
DexCom, Inc. Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 3:02PM CST
DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended September 30, 2014.
DXCM: 50.93 (+6.30)
FDA Approves Dexcom Software with Artificial Pancreas Algorithm
Business Wire - Thu Nov 06, 7:30AM CST
Dexcom, Inc., (NASDAQ
XCM), a leader in continuous glucose monitoring (CGM), announced today that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4(R) PLATINUM CGM. The new Software 505 features the same advanced algorithm as used in artificial pancreas research around the world. The software will impact the performance of the Dexcom G4 PLATINUM, already considered the most accurate CGM system on the market today. The software will be made available free of charge to adult patients using the Dexcom G4 PLATINUM. DXCM: 50.93 (+6.30)
DexCom Announces Upcoming Conference Presentations
Business Wire - Thu Oct 30, 7:30AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that management will present an update on DexCom at the following upcoming investor conferences: DXCM: 50.93 (+6.30)
Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 50.93 (+6.30), NVAX: 4.95 (-0.20), AGIO: 72.06 (-11.03), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), CELG: 106.45 (-0.69)
DexCom Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 at 4:30 p.m. Eastern Time
Business Wire - Thu Oct 23, 7:31AM CDT
DexCom, Inc. (NASDAQ
XCM) today announced that it plans to release its third quarter 2014 financial results after market close on Thursday, November 6, 2014. Management will hold a conference call to review the company's third quarter 2014 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived there for future reference. DXCM: 50.93 (+6.30)
FDA Approves Dexcom SHARE(TM), the First Remote Mobile Communications Device Used for Continuous Glucose Monitoring (CGM)
Business Wire - Mon Oct 20, 8:24AM CDT
Dexcom, Inc. (NASDAQ
XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its CGM remote mobile communications device: Dexcom SHARE. Dexcom SHARE, an accessory to the Dexcom G4(R) PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or "followers." These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere via their Apple(R) iPhone(R) or iPod(R) touch. With Dexcom SHARE, parents and personal caregivers can monitor a child's or loved one's glucose data from a remote location, giving them peace of mind and reassurance when they are apart. DXCM: 50.93 (+6.30)
MFG, PGTI, MWIV, BKD, AREX, DXCM Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Oct 06, 6:29AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mizuho Financial Group Inc (NYSE:MFG), PGT Inc (NASDAQ
GTI), MWI Veterinary Supply Inc (NASDAQ:MWIV), BROOKDALE SENIOR LIVING INC. (NYSE:BKD), Approach Resources Inc (NASDAQ:AREX), DexCom Inc (NASDAQXCM) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: MFG: 3.56 (+0.02), DXCM: 50.93 (+6.30), MWIV: 154.24 (+1.73), PGTI: 9.62 (+0.03), BKD: 32.46 (-0.49), AREX: 10.73 (+1.88)
The Stunning Mobile Game Changer for Diabetics That Investors Can't Ignore
Leo Sun, The Motley Fool - Motley Fool - Sun Oct 05, 8:31AM CDT
Ever since Apple launched the first iPhone nearly seven years ago, developers have released mobile apps and connected devices to improve the lives of diabetes patients. These products helped diabetics track meals, insulin dosages, glucose...
JNJ: 108.20 (-0.81), DXCM: 50.93 (+6.30), MDT: 68.10 (-0.64), SNY: 45.69 (-0.17), AAPL: 109.01 (+0.31)
Technical Report on Health Care Equipment Stocks - Baxter Intl., Covidien, Becton Dickinson, Thoratec, and DexCom
PR Newswire - Wed Sep 17, 8:05AM CDT
On Tuesday, September 16, 2014, the NASDAQ Composite ended at 4,552.76, up 0.75%, the Dow Jones Industrial Average advanced 0.59%, to finish the day at 17,131.97, and the S&P 500 closed at 1,998.98, up 0.75%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index also advancing 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Baxter International Inc. (NYSE: BAX), Covidien PLC (NYSE: COV), Becton Dickinson and Company (NYSE: BDX), Thoratec Corporation (NASDAQ: THOR), and DexCom Inc. (NASDAQ: DXCM). Free research on these five companies can be accessed at:
BDX: 125.54 (-2.39), DXCM: 50.93 (+6.30), BAX: 70.61 (-0.99), COV: 92.08 (-0.52), THOR: 26.93 (+0.83)
3 Reasons Medtronic Inc. Stock Could Rise
Leo Sun, The Motley Fool - Motley Fool - Mon Sep 08, 12:01PM CDT
Last month, Medtronic 's first-quarter earnings topped consensus estimates on the top and bottom lines, as revenue rose 5% year over year to $4.27 billion and non-GAAP diluted earnings climbed 6% to $0.93 per share. Medtronic posted positive...
JNJ: 108.20 (-0.81), DXCM: 50.93 (+6.30), MDT: 68.10 (-0.64), COV: 92.08 (-0.52), STJ: 64.76 (-1.28)
Insider Trading Alert - NATI, DXCM And CNC Traded By Insiders
at The Street - Wed Sep 03, 10:15AM CDT
Stocks with insider trader activity include NATI, DXCM and CNC
CNC: 91.72 (-1.84), DXCM: 50.93 (+6.30), NATI: 32.58 (+0.06)
DexCom Up 14.2% Since SmarTrend Uptrend Call (DXCM)
Comtex SmarTrend(R) - Wed Aug 27, 9:26AM CDT
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on July 30th, 2014 at $40.28. In approximately 4 weeks, DexCom has returned 14.21% as of today's recent price of $46.00. DXCM: 50.93 (+6.30)
DexCom Earnings Hindsight: Up 15.4% in Last 19 Days (DXCM)
Comtex SmarTrend(R) - Mon Aug 25, 7:24AM CDT
19 days ago, on August 6th, 2014, DexCom (NASDAQ
XCM) reported its earnings. Analysts, on average, expected a loss of $0.10 per share on sales of $52.3 million. DexCom actually reported a loss of $0.09 per share on sales of $58.8 million, beating EPS estimates by $0.01 and beating revenue estimates by $6.5 million. Shares of DexCom have climbed from $38.21 to $44.08, representing a gain of 15.4% since the company reported earnings 19 days ago. DXCM: 50.93 (+6.30)
DexCom Has Returned 10.4% Since SmarTrend Recommendation (DXCM)
Comtex SmarTrend(R) - Tue Aug 19, 9:26AM CDT
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on July 30th, 2014 at $40.28. In approximately 3 weeks, DexCom has returned 10.39% as of today's recent price of $44.46. DXCM: 50.93 (+6.30)
DexCom Earnings In Retrospect: Up 14.2% in the Last 12 Days (DXCM)
Comtex SmarTrend(R) - Mon Aug 18, 9:28AM CDT
When DexCom (NASDAQ
XCM) reported earnings 12 days ago on August 6th, 2014, analysts, on average, expected the company to report a loss of $0.10 on sales of $52.3 million. The company actually reported a loss of $0.09 per share on sales of $58.8 million, beating EPS estimates by $0.01 and beating revenue estimates by $6.5 million. Since the company's report, shares of DexCom have risen from $38.21 to $43.62, representing a gain of 14.2% in the past 12 days. DXCM: 50.93 (+6.30)
DexCom Continues to Gain; Enters Data Integration Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:00PM CDT
Asante Snap Insulin Pump is the second insulin delivery device to be integrated into the DexCom, Inc. (DXCM) mobile app, the first being Insulet Corporation's OmniPod System.
ATEC: 1.39 (-0.06), PODD: 43.05 (+0.31), RTIX: 5.09 (+0.02), DXCM: 50.93 (+6.30)
Technical Coverage on Health Care Equipment Equities -- Boston Scientific, Covidien, Thoratec, Baxter Intl., and DexCom
PR Newswire - Wed Aug 13, 8:10AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average declined 0.06%, to finish the day at 16,560.54, and the S&P 500 closed at 1,933.75, down 0.16%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 699.06, down 0.14%, while the index has advanced 3.52% in the previous three months. Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Covidien PLC (NYSE:COV), Thoratec Corporation (NASDAQ: THOR), Baxter International Inc. (NYSE: BAX), and DexCom Inc. (NASDAQ: DXCM). Free research on these five companies can be accessed at:
BSX: 13.24 (-0.12), DXCM: 50.93 (+6.30), BAX: 70.61 (-0.99), COV: 92.08 (-0.52), THOR: 26.93 (+0.83)
